BRAF and melanoma: The mean/median age of all patients was 63 years, most patients were male (59%), had stage IV-M1c disease (69%), an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (74%), a normal lactate dehydrogenase level (57%), metastases in less than three organ sites (52%), no brain metastases (70%), and BRAF-mutated (52%) melanoma.